See which workplaces made this year's list.

2026_GPTW_best-places-by-industry-Manufacturing+Production-GE_HealthCare

Employees say:"I have been working for this company for 5.5 years and I can honestly say that this is a great place to work. I feel seen and heard by my manager and coworkers. My team has a great relationship/bond where we treat each other like family and have each others back. For example, while enduring many &nbsp;organizational changes, I know that my manager has my back and best interest at heart. I feel safe here in knowing that my day to day decisions on how I do my job are valid and backed up."

Best Large Workplaces in Manufacturing and Production

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

2025_GPTW_ManufacturingProduction_Large_GE HealthCare_US1__685d54bb4f22a2fc232770e0_3

Employees say:&nbsp;"Though we are a very large, global organization, we collaborate together at the individual level and there is a strong sense of 'one GEHC.' We are clear on our purpose to keep patients and customers at the forefront of what we do and are often reminded about the global impact we are having in health care, regardless of our role. When someone reaches out to me or I reach out to them, I feel there is a strong sense of servant leadership and desire to help. I continue to be amazed at the colleagues I have met across the globe who know me first as a person and secondly as my role—people genuinely enjoy creating relationships across regions, functions, and segments, which makes work fun, enjoyable, and personable!"

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 62,000 U.S. employees.

Best Workplaces_Chicago_Large_2025-GE HealthCare_US1__67fd6226d94556dd4465c985_3

Employees say:"I have found that at GE HealthCare, this organization is very committed to our values, always keeping our colleagues and patients as the priority and ensuring safety and quality. This is embodied throughout meetings and demonstrated through leaders at all levels. There is a natural strive towards continuous improvement and challenging ourselves and our work to continue to be forward-thinking. It makes the work interesting and exciting, but the best part is that the people here have a mind-set of supporting each other to accomplish the big rocks together and doing it the right way!"

Best Large Workplaces in Chicago

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

Best Workplaces In Chicago

Founded

Sites

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Workplaces In Manufacturing And Production

Industry Vertical

GE HealthCare designs, manufactures, and services advanced medical technology, diagnostics, and digital health solutions. The company’s roots go back to pioneering work with X-ray technology in the late 19th and early 20th centuries. The company is also responsible for the first routine full-body CT scan and key innovations related to MRI and ultrasound scanners. A longtime division and then subsidiary of General Electric, it completed its spinoff as an independent company in January 2023.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

GE HealthCare (GEHC): Company Profile, Stock Price, News, Rankings

legacy

GE HealthCare

ge healthcare

Good day, and thank you for standing by. Welcome to the GE Healthcare First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carolyn Borders. Please go ahead.

Thanks, operator. Good morning, and welcome to GE Healthcare's first quarter twenty twenty five earnings call. I'm joined by our President and CEO, Peter Arduini, and Vice President and CFO, Jay Siccaro. Our conference call remarks will include both GAAP and non GAAP financial results. Reconciliations between GAAP and non GAAP measures can be found in today's press release and in the presentation slides available on our website.

During this call, we'll make forward looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter.

Thanks, Carolyn. Good morning and thank you for joining us. Our first quarter results reflect strong execution as we start the year with revenue and profit growth that exceeded our expectations. Record double digit orders growth as a standalone company was driven by strength in The US market, where we see customers prioritizing investments in imaging products with a particular focus on cardiology and oncology. Early indications from market data shows that we've gained share in a significant number of markets where we compete, reflected in our strong orders growth.

In the quarter, we booked the first Sutter Health orders and continue to strengthen our relationship with many other top IDNs, like our recently announced agreement with St. Luke's University Health Network to drive further growth. We saw strong momentum in backlog and continuing strength in book to bill in the quarter. Top line organic performance of 4% was broad based with growth in each segment, and we delivered healthy margin and earnings per share performance. That being said, we're adjusting 2025 guidance today, reflecting the estimated impact from tariffs on profit and cash.

Our sales estimates remain the same supported by a strong customer demand environment. Let me give a more detailed view on slide four of the current global trade environment. In an effort to be transparent about our view of the environment and its correlation to our business, we're showing on the chart how we expect tariffs to impact our 2025 results if they stay at the current elevated levels. We have conservatively assumed that the bilateral US and China tariffs continue, accounting for 75% of our total net tariff impact. We've also assumed that US reciprocal tariffs on rest of world announced on April 2 returned to pre pause levels on July 9.

And Mexico and Canada tariffs remain in place with USMCA exemptions for all eligible imports. Prior to mitigation, the gross impact of tariffs is estimated to be approximately $1.75 per share. And since we initiated work on tariffs, we've moved swiftly and taken responsible and sustainable actions to mitigate over 50% of our gross exposure. We have a strong funnel of additional opportunities for further offsets, including product and component moves, which take longer to execute. With mitigation actions to date, we expect approximately $0.80 per share of net incremental impact.

This is in addition to the $05 we reflected in our February guidance. To be clear, the total impact of tariffs in our adjusted EPS guidance is $0.85 Given the actions we're taking to optimize the supply chain, in 2026, we expect less than $0.85 of adjusted EPS impact from tariffs under the current tariff structure. Operationally, we're strengthening our market presence and we're on track to deliver our pipeline of innovation discussed at our fourth quarter Investor Day, including radiopharmaceuticals, total body PET, photon counting CT and next generation interventional vascular lab. These are a few of the high impact opportunities we expect to drive growth in 2026. Now I'll turn the call over to Jay to provide more detail on the quarter and guidance for the year.

Thanks Pete. Let's start with our financial performance on slide five. For the first quarter of twenty twenty five, we reported revenues of $4,800,000,000 with solid organic revenue growth of 4%. We reported growth across each of our segments with particular strength in The U. S, where we delivered high single digit growth year over year.

On a reported basis, service revenue grew 3% and product revenue was up 2%. Organic orders growth was robust, up 10% year over year, the highest since our spin. This reflected healthy underlying market demand. Book to bill in the quarter was strong at 1.09 times. We also exited the quarter with a record backlog of $20,600,000,000 up 1,900,000,000 year over year and also up $800,000,000 sequentially.

We continue to make good progress on our margin acceleration, delivering an adjusted EBIT margin of 15% in the quarter, up 30 basis points year over year due to volume and productivity. With mid single digit organic revenue growth, continued margin expansion and lower interest and tax expense, we delivered first quarter adjusted EPS of $1.01 which was up 12% year over year. Free cash flow of $98,000,000 in the quarter was down $175,000,000 from the year ago period, primarily due to timing. I'll cover that later in today's call. This result was ahead of our expectations.

Taking a closer look at margin performance in the first quarter on Slide six, Adjusted gross margin expanded 80 basis points year over year, driven by increased volume and benefiting from higher margin new products. On the cost side, we continue to drive productivity initiatives that are positively impacting margin. For instance, our imaging team has implemented a new lean management system to more effectively convert backlog. This project has reduced our past due backlog by over $25,000,000 increasing customer satisfaction and improving cash flow. For the first quarter, R and D investment was 7% of sales increasing 6% year over year.

We remain committed to advancing our innovation initiatives and growing our product leadership positions. We continue to drive operational efficiency in SG and A while investing strategically in our commercial capabilities, including the launch of our proprietary radiopharmaceutical Blurcato. Our ongoing optimization work and lean approach contributed to the 30 basis point year over year improvement in adjusted EBIT margin. Let's move on to segment performance starting with Imaging on Slide seven. Organic revenue in the quarter was up 5% year over year, driven by strong execution in The U.

S. Segment EBIT margin was up 130 basis points year over year, driven by productivity, volume and price. This expansion versus the first quarter of twenty twenty four was achieved while continuing to invest in R and D for new products expected to launch in the coming quarters. We continue to see robust demand in The U. S.

And EMEA markets as we expand into large enterprise accounts. Turning to Advanced Visualization Solutions on Slide eight, organic revenue was up 3% year over year with strong performance in The U. S. Segment EBIT margin increased by 10 basis points year over year driven by volume and productivity. Our product roadmap is increasingly focused on accelerating recurring revenue with demand for digital and AI across our ultrasound and IGT product portfolios.

Moving to Patient Care Solutions on Slide nine, organic revenue growth was up 2% versus the prior year, driven by continued growth with improved backlog execution in monitoring solutions in The US. EBIT margin declined four fifty basis points year over year due to investments, tariff impact and product mix. The team is focused on delivering new product launches with higher gross margin and driving factory automation and supplier consolidations to improve margin over time. Importantly, we continue to invest in our PCS portfolio, including solutions across digital, consumables and services, which is expected to enable increasing recurring revenue. Moving to Pharmaceutical Diagnostics on slide 10, we delivered another robust quarter globally, generating 8% year over year organic growth and an EBIT margin above 32%.

We were able to deliver this growth while continuing to invest in our R and D pipeline and NPIs. In the first quarter, we made significant progress in executing on our radiopharmaceutical strategy. We delivered the first commercial doses of Flurcado, and we saw continued growth of Visumel. We also completed the acquisition of the remaining 50% stake in Nehaan Metaphysics, which we expect to add approximately $150,000,000 of inorganic revenue over the remaining three quarters of twenty twenty five. Turning to cash on slide 11, we delivered free cash flow of $98,000,000 down year over year primarily due to a shift in the timing of annual employee compensation payments from the second quarter of the year to the first quarter.

We also had an inventory build to support volume growth. We're actively working inventory cycle times and strategically managing our inventory amid the current tariff environment. Our capital allocation priorities remain unchanged. We repaid $250,000,000 of debt in the first quarter of twenty twenty five as we continue to strengthen our capital structure. We're focused on investing in organic growth and pursuing strategic M and A that aligns with our portfolio strategy.

Finally, we remain committed to returning cash to shareholders, and we're very pleased to announce today a share repurchase program authorization from our Board of Directors of $1,000,000,000 Now, let's turn to our outlook on slide 12. In light of the evolving macroeconomic landscape, we're updating our full year guidance, which reflects the strength of our operational execution while incorporating the impact from tariffs as Pete discussed. For full year 2025, we expect organic revenue growth in the range of 2% to 3%, which remains unchanged. Our strong first quarter results and solid backlog give us increased confidence in our top line guidance for the year. Related to China, we continue to take a measured approach.

Consistent with our comments in February, we're assuming China's sales performance will be negative in the first half of twenty twenty five with a sequential improvement in the second half of the year versus the first half, leading to a low single digit decline for the year. While foreign exchange rates have been volatile based on rates where rates are today, we expect FX to be neutral to revenue compared to previous expectations of a 1.5% headwind. Work continually focused on driving cost structure efficiencies that are within our control, though not at the expense of R and D, which is the driver of future innovation. For adjusted EBIT margin, we're now forecasting a range of 14.2% to 14.4% for the full year, compared to our previous guidance of 16.7% to 16.8%. We estimate the incremental tariffs announced since our February guidance will negatively impact adjusted EBIT by approximately $475,000,000 Our adjusted effective tax rate is expected to be in the range of 21% to 22% for the full year compared to 22% to 23% in our prior guidance.

On adjusted EPS, we now expect to deliver between $3.9 and $4.1 for the full year, representing a 9% to 13% decline year over year and down versus our prior estimate of $4.61 to $4.75 Guidance for adjusted EPS includes approximately $0.80 of net incremental tariff impact as compared to the prior guidance. Note, we have not included any potential benefit from share repurchases in our adjusted EPS guidance. Lastly, we now expect to deliver free cash flow of at least $1,200,000,000 for the full year, given the impact of tariff payments. This is compared to our prior expectation of at least 1,750,000,000 Aligned with the timing of the liquidation of higher cost inventory in the P and L, we expect a more significant impact from tariffs in the second half of twenty twenty five versus the first half. We thought it would also be helpful to provide our view of performance for the second quarter of twenty twenty five.

We currently expect year over year organic revenue growth for the quarter to be in the range of 1% to 2%. Including the impact of tariffs, we expect a high single digit decline year over year on adjusted EPS. Overall, if the global trade environment improves and these tariffs are not in place for the entire year or rates decrease in aggregate, we would see a benefit to adjusted EBIT, adjusted EPS, and free cash flow versus what we've shared today. I want to thank our global teams for continuing to innovate and deliver financial results as we manage through a very dynamic global environment. We have the right plans in place to manage the near term and we are focused on delivery and growth for the long term.

With that, I'll turn the call back over to Pete. Pete?

Thanks Jay. Let's move now to some innovation highlights in our business. I've talked in the past about our evolution from being an imaging and equipment company to a healthcare solutions provider. This evolution is deeply rooted in innovation, and as you can see on slide 13, some of the key NPIs launched in the first quarter are helping to enable personalized care in cardiology throughout the patient journey. Recently, I attended the American College of Cardiology meeting where we officially launched Forcado, our first of its kind pet myocardial perfusion imaging agent to detect coronary artery disease.

I'm excited to share that we received CMS pass through pricing for this novel tracer, and we're on track with our planned rollout. At ACC, we also introduced a dedicated cardiac CT system revolution vibe focused on a variety of cardiac tests, including coronary CT angiography. These types of exams are expected to increase now at global guidelines and reimbursement levels make it more financially viable. To wrap up on slide 14, we're very pleased with our strong start to the year with record orders and strong top line growth, driven by performance across all of our segments. Customers have a positive sentiment around existing GE Healthcare solutions and are excited with our pipeline of new products.

And there's strong demand in many of our markets that we serve. I'm proud of how our teams are executing on our precision care strategy and going above and beyond in dealing with the macro challenges. Our commercial teams are winning and we're making a difference in the eyes of our customers. As we discussed earlier, we have dedicated teams focused across our supply chain, executing actions to reduce our tariff impact today and into 2026. Some plans we can implement quickly, others will take months.

At the same time, we're carefully managing discretionary expenses across the company while maintaining long term innovation investments. We'll continue to focus on what we can control to protect margin, earnings and cash flow. Before we open up the call for questions, I'd also like to welcome Jeanette Bankis, who is joining us in May as our new CEO of Patient Care Solutions. Jeanette is a well respected global leader in med tech who brings more than thirty years of experience at public companies. We're thrilled to have her as part of the team and we look forward to her leadership contributions in advancing our Precision Care strategy.

With that, let's open up the call for questions.

Thank you, Peter. I'd like to ask participants to please limit yourself to one question and one follow-up. Operator, can you please open the line?

Thank you. And as a reminder, to ask a question, please press 1, 1 on your telephone And our first question will come from Larry Biegelsen from Wells Fargo. Your line is open.

Good morning. Thanks for taking the question and congrats on a strong start to the year here. I wanted to ask one on tariffs and one on China. Let me start with the tariffs. Jay, I'd love to hear more about the tariff impact from you.

The $0.85 in 2025 is a partial year. It looks like you expect the impact to be lower than $0.85 next year in 2026. How are you achieving that? And how would the pharma tariffs impact that? And second, talk about the cadence of the tariffs.

I assume the impact is greatest exiting this year given inventory turns. Thanks.

Sure. Larry, as it relates to tariffs, this year we estimate $0.85 of impact, which is predominantly centered in Q2, Q3 and Q4. If the tariffs remain at elevated levels that they are at today in terms of actual tariff levels in place, our expectation is that next year we will be below $0.85 And really what we've done to date is a lot of sort of more straightforward mitigation. So duty drawback, USMCA compliance, bonded logistics routes, All of those are more simpler, more straightforward, they require work, but that's the predominant number that we're seeing run through in terms of offsetting impacts in 2025. As we look at 2026, there are a number of incremental moves that we would make.

And remember, our company coming out of COVID, we did a lot of work on sourcing and making our products where they're consumed, And we did a lot of work on dual sourcing. We would continue and accelerate some of that. So we would look to shift manufacturer more local for local. There are a number of dual make opportunities for us. And then from a supplier standpoint, we're currently hard at work looking at multi sourcing supply.

And so those are some of the tactics that allow us to mitigate even further the impacts in 2026. Now, you asked the question around cadence of impact. In the first quarter, we had a very small impact from tariffs, maybe around $10,000,000 But as we move into the second quarter and the third and fourth quarter, the impact is more dramatic. In the second quarter of this year, we expect less than $100,000,000 of impact, a little bit less than $100,000,000 And then in the third and fourth quarters, it's around $200,000,000 of impact. And a lot of that has to do with the timing of when higher cost inventory runs through the P and L.

So as we look at 2026, the first quarter of the year will have a similar level of impact to the fourth quarter, but then the mitigations that we're putting in place start to rapidly impact that as it draws down over the course of the rest of the year. So really, think that hits the question in terms of timing of cadence this year along with impact next year.

That's super helpful, Jay. And then on China, it looks like it improved significantly in Q1. Color on what you're you gave the cadence that you expect this year. Just color on what you're seeing there and how you're thinking about the potential impact of VBP? Thank you.

Hey, Larry, it's Pete. Look, I think and as we said in the prepared remarks, China hasn't materially changed from what we've laid out from our expectations, even back as we've talked about in Q4 and I think kind of confirmed in the first quarter discussion. We still expect mid single digit decline in the first half. We would expect probably Q2 to be one of the more tougher quarters just relative to how we look at the compares and the challenges, and then sequentially improve in the second half. And there's no indications that we've seen market wise that that's changed.

I know others have reported potential rebounds, different messaging in the marketplace. I think we've been rather consistent here. And we watch a lot of how the tender money is being released that we judge that on. So I think that is how we see that playing out. You asked about VBP, part of our strategy and plans this year were to factor that in.

Again, VBP obviously is a very specific item on this value based procurement, but we've seen bulk tender buys over the years. These just become more intense bulk tender buys by province. We have specific configurations that we offer in those type of constructs. Our distribution network and the cost of go to market is different when we enter into those deals. So I would say at this point in time, it's pretty much aligned to what we had assumed relative to 2025 China.

Thank you. And our next question will come from Jason Bednar from Piper Sandler. Your line is open.

Good morning. Nice quarter, everyone. I appreciate all the details you provided here today on the tariff dynamics. Like Larry, I want to focus first on that topic and the mitigation efforts that are now contemplated in today's guidance. You already had cost saving efforts in motion for this year and obviously planned for future years.

Are the actions you're taking to mitigate tariffs, these are probably more in the 26 variety than some of the immediate things you're doing here, but are these a pull forward of actions that were contemplated in your LRP, I guess, directly on a long term basis? Like, how should we be thinking about the net effects of tariffs mitigation efforts in the context of the LRP that you provided at the Investor Day back in November?

Yeah, Jason, look, I mean, it's obviously early. There's a lot of variables that are out there, but our views on the medium term here, we laid out Investor Day have not changed, just to be clear about it. I think the pathway might be slightly different. Obviously, as we lay out strategies and plans, this wasn't fully laid out maybe a year ago. But we have many levers that we can pull to be able to deliver on this.

This business has tremendous margin and growth potential. So nothing has changed from that. And so, look, we're taking a prudent view of the current trade environment and the impact on the business. I think you've seen the numbers we've laid out. We basically said that the numbers we're discussing stay at these elevated levels, rest of world China throughout this whole time period.

So as we move into these scenarios, even if those rates come down, we're gonna be quite aggressive on what we can do to make local for local in different marketplaces, move aggressively as Jay said on dual supply scenarios. And also how we take a look at our overall configuration constructs to better position us as we go forward. But I feel quite good about our margin potential of this business and ultimately over the long term, what that means from how we view the profit capability, as well as the growth capabilities of GE Healthcare.

All right, very clear, thank you. And then for my follow-up, lot of other changes implemented by the current administration beyond just tariffs, including budget cuts and headcount reductions at key healthcare agencies. Have you seen any downstream impacts on your business from these actions? Have your interactions with the FDA changed at all? And maybe sorry to pack in a couple here, but really interested to hear how you're thinking about the photon counting CT submission that's planned for later this year, and if that submission timing is still on track in light of all the changes at the FDA.

Yeah, Jason, thanks. I would say in short, we haven't seen any impacts from any of the administrative changes at this point, whether they be on the cost other items at this point in time. Obviously, there's a lot of concern. I think the NIH funding discussions hits many of the academics. Could there be changes there?

I suppose there could, but we haven't seen anything specifically that has come through from that. And from the FDA standpoint, at this point in time, there were some bigger cuts, there actually were employees brought back in from our submissions on 510s primarily and what we're counting on. We currently don't see any delays from that standpoint. Now, those things could change just based on how that plays out. But at this point in time, we as far as speaking for our plans of new product approvals, how we see the market and how our customer base is prioritizing their spend, we haven't seen any specific impact that would be notable, I'd say at this point in time.

All right, very helpful. Thank you, Pete.

Thank you. Our next question comes from Vijay Kumar with Evercore ISI. Your line is open.

Hey guys, good morning and thank you for taking my question. Maybe my first one on sort of related to China in tariff. Jay, helpful comments there on your 75% of tariff headwinds being related to China US. What portion of that is US to China versus China to US? I think there was some talks maybe of exemptions from China.

Any update on that? I think from China to U. S, what products are you importing? I think there was talk of exemptions under Annex II for Radio Farm. If these tariffs were some of these headwinds were to be rolled back, what is the upside to guidance here?

Sure. Vijay, as we said in the prepared remarks, total tariff impact around $500,000,000 for the full year, and the bilateral China tariffs are the most significant impact for us at around $375,000,000 That's roughly 65 of the $0.85 of impact that we're experiencing. And it really goes both ways. We do ship a fair amount of product from US to China and vice versa. We have not included any unplanned exemptions, and we're not really seeing a positive impact from exemptions nor are we counting on that.

But just to frame it for you, and I'm not suggesting that we think this is a likely scenario, but in one hypothetical scenario, if The US China agreement, let's say that went into effect on May 1, and you had both sides improve 100 points. So China goes from 45 from the 145 today to 45 and China exports go to $25 from $1.25 today. We estimate that this would be a benefit to EPS of approximately $0.40 for the year. So it's a big number for us. These are large tariff numbers that we have in place.

So we'll watch very closely the scenario and how this plays out. Maybe Pete, if you would add something.

Yeah, I'd say Vijay, we're a big exporter from The United States into China. We've been doing this for a long period of time, some of our higher technology and x-ray generation, some of our componentry and MRI and stuff. And so that's a big part of the number that we actually export into that. And so that gets hit by those, Jay said, the 125 tariff. And then there are select components in areas that we pull out of China that feeds other plants around the world.

And so even though we may manufacture the whole product in The United States or other areas, you may have 20% of the components coming from one of these countries with the high tariff areas. And so that's why the concentration exists. And obviously, there's changes that take place in there, that'll have a bigger benefit. If it doesn't, we have opportunities and plans to do much more local for local, and actually work our supply base across our 43 plants to feed that. And when I talk about it takes months to get there, those are the things I'm referring to, but we have all those levers in front of us if we need to go there.

And that's part of our plan to be able to execute on that.

That's helpful Pete. And maybe my follow-up here on free cash, it was lowered by maybe $05,000,000,000 Is that all tariff impact? I think you said tariff was $05,000,000,000 head or anything else going on in free cash flow?

Yes. Thanks, Vijay. Just as an aside, we were pleased with the free cash flow in the first quarter and it was a really nice start to the year. We did lower to at least $1,200,000,000 and this was exclusively due to tariff payments. Basically, it's the P and L impact that I described.

There's some benefit from cash tax impact from that we pay, but then the offset is the higher costs and tariffs impact inventory and cash flow first before they're liquidated to the P and L. So what we're seeing is the buildup in this year, and that's what causes this $550,000,000 reduction that we've highlighted. At this point, there's no other changes to free cash flow. We're continuing to stay very vigilant. We think the business is a very strong cash generator, and we're still driving operational working capital improvements.

But this tariff impact is something that we're working through.

Thank you. Our next question will come from Robbie Marcus from JPMorgan. Your line is open.

Great. Congrats on a good one, queue. Two for me. Wanted to ask first on Flurcato and how that's going. And then I'll ask second here.

Just sort of the environment in China, we saw the anti dumping allegations get announced not against GE Healthcare specifically, but just on the industry. How are you viewing that? Any expected change? How do you think you fit in there? And just a quick clarification on whether the pharmaceutical diagnostics are included or excluded in tariffs here.

I think you touched on it, but just wanted to get a firm answer. Thanks a lot. Appreciate it.

Yeah, Robbie, thanks for the questions. Maybe I'll start out with Flurcato, and then we'll talk a little bit about the next components that you had. So look, on Flurcato, we're feeling quite good about it. I think as we mentioned in the comments, we're pleased with the progress. We've talked about launch in April.

We've hit that, we're on track. We've talked about roughly $30,000,000 of revenue in 2025 and we're well lined up to that. It takes time to ramp these again as we bring up the sites and because it is a radiopharmaceutical manufacturer local to the relationship of where it's consumed. And so we're expanding our CMO contract manufacturing organization throughout The US. I'd say that is right on track to where we are.

We're north of a dozen sites and that'll double by the end of the year. But the feedback has been good, clinically, the image quality superior to really anything out there on the myocardial perfusion front. Ultimately, the specificity sensitivity to tick to deck disease will come through based on that. There's benefits of the half life and distribution versus the predicate product, so to speak today, rubidium and the generators. All the scenarios that we've laid out look good.

I'd say, the couple of big things we've done the first dosing here in mid February, it's gone well. Commercial launch, as I mentioned at the American College of Cardiology, a lot of interest there. And then this pass through status from CMS on reimbursements, big deal, and that was approved on April 1. So we're off and running and things look good. There's a lot of interest within the product.

Yeah, so there was a question on the China market and some of the anti dumping.

Yeah, look, I think across the globe, I think from a standpoint of sentiments with us or American companies and stuff, we haven't seen any negative effects or anything relative to Mark. As we mentioned, we've seen that aligned. This point about this anti dumping discussion, yes, there was a communication, it stemmed from a complaint from a private company that named a significant amount of multinational companies from around the world. And included, not just again, obviously us. I think that's really important.

It didn't originate from the government. It originated from a complaint of a private company. And so we don't believe this investigation is material risk to our business in China. Back on, I'd say just in April 6, us among other companies had a meeting with the Ministry of Commerce. And it underscores kind of the discussions about fair treatment and there were positive comments expressed about us obviously not being targeted.

We've had numerous discussions obviously with many officials since the tariffs and things have taken off as well and have seen support to be able to have us continue to be obviously an important player within that marketplace. So again, I don't see anything that comes out of there as course of normal business relative to things that happen in different marketplaces. And your last point, I think, Robbie, was on pharma and the tariff discussion. Jay, do you want to hit

Sure. So Robbie, we haven't included any potential 2 30 2 tariff impacts in the guidance. Our approach is to include tariffs that have been announced and are quantifiable. Our PDX business has products that are principally used in tandem with imaging equipment, so it's not clear at this point where that would fall and whether these products would be in scope of potential $2.32 tariffs.

Our PDX business has positive pricing dynamics, so we'll have to watch that. So we'll watch this as it evolves and address it appropriately.

Appreciate it. I think we're all trying to figure out some of the nuances So, if you don't know, I'm pretty sure we don't know either. Thanks a lot.

Thank you. Our next question will come from David Roman from Goldman Sachs. Your line is open.

Thank you. Good morning. I wanted just to start on tariffs. I like I know we've covered this extensively, but there are a lot of moving parts here. Some of it is clearly just math and some of it is operational.

Can you help us understand the magnitude of mitigation actions that are already in place versus those that need to be implemented? In that same context, how you're thinking about sustaining investment in the business in SG and A and R and D? Then I have a follow-up on the strategic side.

Sure. First, as it relates to SG and A and R and D, we're obviously very focused in this environment on controlling spending. So things like travel, headcount, we're very disciplined on these areas. And furthermore, with respect to our productivity initiatives, we are continuing an intense focus on those areas. At the same time, we're protecting key investments in R and D in terms of the pipeline and how this is going.

And we're also protecting critical investments in sales and marketing to support some of these great launches that we have. So that's the philosophy on SG and A and R and D and spending controls. I would say that's really what we have in place. The only thing I would add is we are earmarking a portion of money for the fact that there will be spending that takes place this year that supports incremental mitigation efforts next year in terms of tariff offset. So we've allocated some money to that in the second half of the year.

Now, as it relates to your question on mitigation and tariffs, we've a significant amount of work and we have a very clear line of sight to essentially all of the savings that we've earmarked for this year. And so that includes things like duty drawback, completed USMCA, tariff code exemptions. We spelled out some of it on the slide, but it's safe to say we have a very long project plan that supports this. And then as we go to next year, we have a very long funnel of opportunities, but some of the implementation will depend upon the final nature of the tariff agreements that are in place. And so we have to wait and see a bit how things settle out before we lock in on all of those.

But as I said, we have a very solid funnel that's outlined to support the achievement of next year's number. Pete, what would you add?

Yeah, David, think Jay, you covered it well, but just to give some more examples here is we obviously want to see how the tariff matrix plays out around the world because you don't want to initiate a move until you actually understand what that rate may look like where you would move to another country. There's some no regret moves Jay touched on those. But the three orders of things are we make a lot of the same products in the same country. So you can actually throttle down one plant throttle up another. We're already in the midst of doing that.

I think in our vascular business, in our molecular imaging business, in our CT business, we have the potential to do all of those type of things. The next is we source and make components in many different places. These are from our own core plants. And so where we might be making something in The U. S.

To go to another area or some other country to come to Western Europe or The U. S, we can actually change the mix of that. And so in some cases that the exact product might not be there and a transfer is pretty straightforward because all the core competencies exist to do that. And the third would be, we have a big supply base. And many of our suppliers are global suppliers and they are making it in this country versus that country.

We can have them switch and ramp that up. All those are the games in play and they take multiple months to move, but that's why we have confidence in second half of this year and going into '26 that we can have significantly larger mitigation efforts.

Appreciate all the color. And maybe just a follow-up here. Considering what look obviously broader market dislocation here, how are you thinking about M and A? Like isn't this a prime environment to kind of accelerate those efforts as whether short term disruptions create some obviously noise around what you guys might otherwise consider long term structural winners in categories like monitoring or diagnostics?

Yeah, David, I think you're right on. I mean, we've been very clear about our capital allocation strategy is organic investments and then finding the right types of tuck in M and A. We obviously announced other levers that we're executing on, but M and A is a critical one for us. We've got a strategy we've talked about, about expanding our top line growth as well as growing our margins. So as we look at opportunities to bring into the portfolio, that's absolutely right.

GE HealthCare (GEHC) Q1 2025 Earnings Call Transcript

Company Participants